Articles added in the last year, sorted by date
Somatic CpG hypermutation is associated with mismatch repair deficiency in cancer
M WaszakSebastian�- Molecular Systems Biology, 2024 - embopress.org
2 days ago - Somatic hypermutation in cancer has gained momentum with the increased
use of tumour mutation burden as a biomarker for immune checkpoint inhibitors�…
use of tumour mutation burden as a biomarker for immune checkpoint inhibitors�…
[HTML][HTML] Impact of Genomic Mutation on Melanoma Immune Microenvironment and IFN-1 Pathway-Driven Therapeutic Responses
FM Mentucci, EA Romero Nu�ez, A Ercole, V Silvetti…�- Cancers, 2024 - mdpi.com
3 days ago - Simple Summary This study investigates the impact of the BRAFV600E
mutation, present in half of melanoma cases, on immune microenvironment and therapeutic�…
mutation, present in half of melanoma cases, on immune microenvironment and therapeutic�…
[HTML][HTML] Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma
TE Richardson, JM Walker, D Hambardzumyan…�- Acta�…, 2024 - Springer
3 days ago - In recent years, the classification of adult-type diffuse gliomas has undergone
a revolution, wherein specific molecular features now represent defining diagnostic criteria�…
a revolution, wherein specific molecular features now represent defining diagnostic criteria�…
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study
C Chen, EJ Dettman, W Zhou, A Gozman, F Jin…�- Future�…, 2024 - Taylor & Francis
9 days ago - Aim: To determine the prevalence of deleterious mutations in BRCA1 and
BRCA2 and in 13 genes involved in homologous recombination repair (HRR), the�…
BRCA2 and in 13 genes involved in homologous recombination repair (HRR), the�…
Durable Response of Pembrolizmab for EGFR Mutation-positive Lung Adenocarcinoma with Early Progression to Osimertinib in First-line Treatment
A Miyazaki, K Saruwatari, T Yamanaka, K Shiraishi…�- Internal�…, 2024 - jstage.jst.go.jp
10 days ago - Osimertinib, a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), is the standard first-line treatment for EGFR mutation-positive�…
kinase inhibitor (EGFR-TKI), is the standard first-line treatment for EGFR mutation-positive�…
[HTML][HTML] Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers
L Shang, X Jiang, X Zhao, X Huang, X Wang…�- Cell Reports�…, 2024 - cell.com
11 days ago - Low migratory dendritic cell (DC) levels pose a challenge in cancer immune
surveillance, yet their impact on tumor immune status and immunotherapy responses�…
surveillance, yet their impact on tumor immune status and immunotherapy responses�…
Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker
C Yang, B Ni, L Shen, Z Li, L Zhou, H Wu…�- The FASEB�…, 2024 - Wiley Online Library
11 days ago - Abstract Intercellular adhesion molecule 1 (ICAM1) is a cell surface adhesion
glycoprotein in the immunoglobulin supergene family. It is associated with several epithelial�…
glycoprotein in the immunoglobulin supergene family. It is associated with several epithelial�…
[HTML][HTML] The Latest Look at PDT and Immune Checkpoints
D Aebisher, A Przyg�rzewska…�- Current Issues in�…, 2024 - mdpi.com
12 days ago - Photodynamic therapy (PDT) can not only directly eliminate cancer cells, but
can also stimulate antitumor immune responses. It also affects the expression of immune�…
can also stimulate antitumor immune responses. It also affects the expression of immune�…
Next‐generation sequencing identifies that protein tyrosine phosphatase receptor type D mutation is favorable to immunotherapy in human cancer
Y Huang, J Liao, M Gao, S Fu, F Liang…�- MedComm�…, 2024 - Wiley Online Library
13 days ago - Protein tyrosine phosphatase receptors (PTPRs) play a crucial part in
numerous tumor processes. However, the effect of PTPR mutations on the immune�…
numerous tumor processes. However, the effect of PTPR mutations on the immune�…
[HTML][HTML] Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS-and NF1-(“Triple”) wild type melanomas
P Jansen, W Galetzka, GC Lodde, F Standl…�- European Journal of�…, 2024 - Elsevier
14 days ago - Background Melanomas lacking mutations in BRAF, NRAS and NF1 are
frequently referred to as “triple wild-type”(tWT) melanomas. They constitute 5-10% of all�…
frequently referred to as “triple wild-type”(tWT) melanomas. They constitute 5-10% of all�…